

## **Tim Maughan**

### **Activities**

#### **Clinical Research Collaboration Cymru**

In 2006, the Wales Office of Research and Development funded the CRC Cymru. Professor Maughan directs the Coordinating centre which has the responsibilities to establish and manage a research professional network covering clinical research across many specialties, in social care, primary and secondary care.

#### **Wales Cancer Trials Network**

This clinical research programme has been jointly funded by the Welsh Assembly and Cancer Research-UK since 1998. Its objectives are to improve recruitment to national clinical trials throughout Wales and to instigate, support and service trials originating in Wales. In 2003 the CR-UK and NAW reviewed the work for a programme grant and rated it as at the forefront internationally both for past and future work. Its objective of recruiting over 10% of incident cancer patients into clinical trials was achieved in 2006.

#### **National Cancer Research Network Operational Steering Group**

As the current Chair of the NCRN OSG, Prof Maughan works with a small core group within the NCRN reviewing the performance of the cancer research networks across the UK, and is involved in the appointment of Chairs and members of the clinical studies groups and the three yearly reviews of the CSG performance.

#### **Wales Cancer Trials Unit**

In 2005, the developing clinical trials unit formed from within the WCTN, working with the Centre for Health Service Research in Cardiff University and in a mentorship relationship with the MRC Clinical Trials Unit, was accredited by the NCRI.

#### **Colorectal cancer**

Professor Maughan is a long standing member of the NCRI colorectal clinical studies group and chairs the advanced disease subgroup. That subgroup has initiated the following studies:

- MRC CR06: A multicentre study of two durations and three regimens of chemotherapy in metastatic colorectal cancer. CI TSM.1995-2001. Published in the Lancet (x2) and BJC.I NCRI FOCUS trial (MRC CR08) of palliative chemotherapy in advanced colorectal cancer: (CI M Seymour).
- NCRI FOCUS-2 (MRC CR09): trial of adjuvant chemotherapy following radical chemoradiation and resection of rectal cancer: (CI M Seymour).
- NCRI COIN (MRC CR10) trial: Chief Investigator TSM (see below)
- NCRI PICCOLO trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus cyclosporin TMG and grantholder (CI M Seymour).

#### **MRC COIN trial**

The COIN trial is a three-arm randomized controlled trial compares either Continuous chemotherapy plus

cetuximab or Intermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer. 2421 patients will be recruited over the next 3-4 years. An extensive translational programme is in place evaluating the effect of variance in DNA repair genes on outcome (Cheadle, Cardiff CR-UK), pharmacogenomics of all agents involved (Macleod, St Louis, NIH), EGFR IHC and other markers for prediction of response of paraffin sections and a tumour collection for microarray analysis using specific cDNA microarrays for colorectal disease (Johnson, Arradix, Belfast).

### Recent publications

1. Richard A Adams, Matthew Morgan, Somnath Mukherjee, Alison E Brewster, Tim S Maughan, Dave Morrey, Tim Havard, Wyn Lewis, Geoff Clarke, S Ashley Roberts, L Vachtsevanos, J Leong, Richard Hardwick, David Carey, and Tom D.L Crosby. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. GUT/2006/099200.
2. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP. Pharmaco- economic analysis of adjuvant oral
3. capecitabine versus intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial Br J Cancer July 2006
4. Segal S, Taberner J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan TS, Morere J, Santoro A, Sobrero A, Van Cutsem E, Layton A. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005 Aug;3 (8):599-606..
5. ReaD, Nortier J, Ten Bokkel Huinink W, Falk S, Richel, Maughan TS, Groenewegen G..C.J.A. Punt. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first line therapy for advanced colorectal cancer. Annals of Oncology, June 2005, published online.
6. Hoskin PJ, Smith P, Maughan TS, Gilson D, Vernon C, Syndikus I, Linch DC Long term results of a randomised trial of involved field radiotherapy versus extended field radiotherapy in stage I and II Hodgkin lymphoma Clin Oncol 17(1):47-53, 2005
7. Finlay IG, Williams SM, Maughan TS & Robbe IJ. Does student teaching harm or help cancer patients? Medical Education (accepted for publication Nov 2005)
8. Brown G, Davies S, Williams GT, Bourne MW, Newcombe RG, Radcliffe AG, Blethyn J, Dallimore NS, Rees BI, Phillips CJ, Maughan TS. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004 Jul 5;91(1):23-9.